Subchronic rat inhalation study with Skydrol 500B-4 fire resistant hydraulic fluid.
Skydrol 500B-4 fire resistant hydraulic fluid, a proprietary phosphate ester mixture composed principally of dibutyl phenyl phosphate (DBPP) and tributyl phosphate (TBP) and used as a commercial airline hydraulic fluid, was evaluated in an inhalation toxicity study of Sprague-Dawley rats. Target exposure levels used in the study were 0, 5, 100, and 300 mg/m3, and exposures were maintained for 6 hr/day, 5 days/week. Mass median aerodynamic diameters determined for particles in the mid- and high-exposure inhalation chambers were 2.85 microns and 3.31 microns, with geometric standard deviations of 1.99 microns and 1.92 microns, respectively. The percentage of particles less than 10 microns in diameter were 96.4% in the mid-exposure chamber and 95.5% in the high-exposure chamber. After 6 weeks of Skydrol exposure, 10 rats/sex/group were euthanized and then assessed for indications of possible chemical toxicity. Another 15 rats/sex/group were studied for a total of 13 weeks of exposure. The only clinical sign of chemical toxicity was the observation of a reddish nasal discharge with accompanying oral salivation in mid- and high-exposure animals of both sexes, indicative of an irritant response. Statistically significant reduced body weights; increased absolute and relative liver weights; and decreased erythrocyte counts, hemoglobin levels, and hematocrit values were observed in high-exposure female rats euthanized after 13 weeks of Skydrol exposure. High-exposure male rats also had increased absolute and relative liver weights and decreased hematocrit values after 13 weeks. Plasma cholinesterase levels were decreased in high-exposure female rats both 6 and 13 weeks after the study was initiated.(ABSTRACT TRUNCATED AT 250 WORDS)
Healy
C E
CE
Monsanto Company, St. Louis, MO 63167.
Nair
R S
RS
Ribelin
W E
WE
Bechtel
C L
CL
D000280:Administration, Inhalation; D000401:Aircraft; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002802:Cholinesterases / Q000097:blood; D004353:Drug Evaluation, Preclinical; D004906:Erythrocyte Count; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D007958:Leukocyte Count; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010755:Organophosphates / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D012140:Respiratory Tract Diseases / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology
D006454:Hemoglobins; D010755:Organophosphates; C025742:dibutyl phenylphosphate; C009524:tributyl phosphate; D002802:Cholinesterases